Sulfonylurea receptor 2B (SUR2B)

Sulfonylurea receptor 2B (SUR2B) is a splice variant of the ABCC9 gene encoding a regulatory subunit of ATP-sensitive potassium (K\(_\text{ATP}\)) channels. These channels consist of four Kir6.x subunits and four SUR subunits, forming a complex that links cellular metabolic status (ATP/ADP levels) to electrical activity across the membrane. SUR2B is primarily expressed in vascular smooth muscle, where it regulates K\(_\text{ATP}\) channel gating, sensing nucleotides, and facilitating channel closure or opening accordingly[1][4][2]. The channel is a target for sulfonylurea drugs, which bind SUR subunits to induce channel closure, altering cell excitability and downstream physiological functions. SUR2B\u2019s function has implications for cardiovascular regulation and is a relevant target for antidiabetic and investigational cardiovascular therapeutics[8][3].

Other names

SUR2BATP-binding cassette sub-family C member 9 variant BABCC9-BSulfonylurea receptor type 2B

Drugs binding SUR2B close the K\(_\text{ATP}\) channel, depolarizing the cell membrane. Channel inhibition reduces potassium efflux, leading to downstream effects such as muscle contraction or altered vascular tone.